Comprehensive information about experimentally validated enhancers
| Enhancer ID: | E_01692 |
| Species: | Homo sapiens |
| Position : | chr5:53031762-53032075 |
| Year: | 2025 |
| Title: | Enhancer-Associated LncRNA-ITGA2 Promotes Vascular Remodeling Through ITGA2. |
| Genome Build: | hg38 |
| Enhancer Type: | Enhancer |
| Condition: | Disease |
| Disease Name: | coronary artery disease |
| PMID: | 40321134 |
| Tissue: | vasculature |
| Tissue Ontology ID: | UBERON:0002049 |
| Cell Source: | Primary human vascular smooth muscle cells |
| Cell Type: | vascular associated smooth muscle cell |
| Cell Ontology ID: | CL:0000359 |
| Experiment Type: | Enhancer activity assay; Chromatin interaction assay; Enhancer-associated lncRNA functional perturbation assay; RNA-chromatin interaction assay; RNA-protein interaction assay; Endogenous enhancer perturbation; Chromatin-state profiling; In vivo functional validation |
| High Throughput Method: | H3K4me1/H3K27ac CUT&Tag; Promoter capture Hi-C; lncRNA microarray; RNA-seq; H3K27ac ChIP-seq; ChIRP-MS; ChIP-seq |
| Low Throughput Method: | ChIRP-qPCR; RIP-qPCR; NONO ChIP-qPCR; CRISPR-Cas9 gene editing; LncRNA-ITGA2 gain- and loss-of-function; RT-qPCR; Western blot; VSMC proliferation assay; VSMC migration assay; CRISPR-Cas9 endogenous deletion/editing; ChIP; In vivo phenotyping |
| Target gene : | ITGA2 |
| TF name : | NA |
| Regulatory State : | Active |
| GeneName | Pathway Name | Source | Gene Number |
|---|